Alteogen – Talk Bio

Actionable Insights Powered by AI

AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes

1 month ago talkbio0Tagged Alteogen, AstraZeneca, Enzymes, Halozyme, hyaluronidase, Legal patent, licensing agreement, Merck, Subcutaneous Cancer

AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme

Daiichi Sankyo and Alteogen Collaborate on Subcutaneous Enhertu Development in $300M Licensing Agreement

6 months ago talkbio0Tagged Alteogen, Cancer Therapeutic Procedure, Daiichi, Enhertu, Homo sapiens, hyaluronidase, Sankyo, subcutaneous

Daiichi Sankyo, Alteogen, subcutaneous Enhertu, $300M licensing deal, human hyaluronidase, cancer treatment